Harrow, Inc. · NASDAQ:HROW
Harrow — Harrow Health — Investor Presentation (August 2022)
10 slides from Harrow's investor presentation, August 2022
Slide 1: Corporate Presentation | August 2022
Corporate Presentation | August 2022 1
Slide 2: Safe Harbor
Safe Harbor . This presentation contains express “forward-looking statements” as defined in the U.S. Private Securities Litigation Reform Act of 1995. You are cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying
Slide 3: Harrow Health, Inc. (NASDAQ: HROW)
Harrow Health, Inc. (NASDAQ: HROW) . o Commercial stage ophthalmic-focused pharmaceutical company headquartered in Nashville, TN. o Serves the U.S. surgical, acute, and chronic care markets with branded FDA-approved products (BPPs) and cGMP compounded products (CPPs); 10,000+ customers (doctors, hos
Slide 4: Harrow’s Eyecare Pharmaceuticals Platform
Harrow’s Eyecare Pharmaceuticals Platform . o A vertically integrated pharmaceutical and pharmacy platform and trusted ophthalmic brand (ImprimisRx), consisting of national sales and customer service teams, automated cGMP drug compounding facilities, and an efficient, scalable, and tech-enabled nati
Slide 5: Revenues, Core Gross Margin and Assets
Revenues, Core Gross Margin and Assets . (Revenues and Assets in Thousands) $106,966 $98,329 $98,062 75% 76% 74% 70% 67% $72,476 60% 51% $59,085 $57,474 50% 46% $49,451 $51,165 $48,871 $45,443 34% $41,372 $33,577 $27,247 $26,774 $23,917 $19,942 $14,131 $10,242 $9,716 $1,660 2014 2015 2016 2017 2018
Slide 6: Adjusted E(L)BITDA Growth and Expense Control
Adjusted E(L)BITDA Growth and Expense Control . (Dollars in Thousands) $19,473 199% $9,974 $9,445 130% $5,700 $4,600 95% $200 77% 73% 73% 70% 64% $(7,000) 55% $(10,000) $(10,000) 2015 2016 2017 2018 2019 2020 2021 1H21 1H22 Adjusted E(L)BITDA Operating Expense as a % of Revenue 6 6
Slide 7: 2022 Prospective Value Drivers
2022 Prospective Value Drivers . Pre- Commercialization 2022 Compounded Branded Drug Branded Products Products Expected Candidates Relaunched to Launch AMP-100 Ocular anesthetic drug candidate • PDUFA target action date of Oct. 16, 2022 • TAM of 12.5M annual U.S. procedures (4.5M cataract surgeries;
Slide 8: Equity Holdings and Royalty Pipeline
Equity Holdings and Royalty Pipeline . o Surface Ophthalmics, Melt Pharmaceuticals, and Eton Pharmaceuticals (NASDAQ: ETON), founded as Harrow Health subsidiaries, were carved-out after hiring management and closing external financings. o Harrow owns: • 2 million shares of Eton and equity in Surface
Slide 9: Summary of Harrow Health (NASDAQ: HROW)
Summary of Harrow Health (NASDAQ: HROW) . o 2022 expectations: Growing revenues, stable gross margins and OpEx/revenue ratio. o Completed seven accretive/consequential deals during last 24 months; others in various stages of progress. o Revenues expected to double within a few years of the AMP-100 p
Slide 10: 102 Woodmont Blvd., Ste 610 Nashville, Tennessee 37205
102 Woodmont Blvd., Ste 610 Nashville, Tennessee 37205 www.HarrowInc.com Jamie Webb Director of Communications and Investor Relations jwebb@harrowinc.com Direct: 615-733-4737 10 10